Cargando…

Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer

BACKGROUND: Patients with stage I-III gastric cancer (GC) undergoing R0 radical resection display extremely different prognoses. How to discriminate high-risk patients with poor survival conveniently is a clinical conundrum to be solved urgently. METHODS: Patients with stage I-III GC from 2010 to 20...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Weiqiang, Cai, Zerong, Sheng, Nengquan, Yan, Li, Wan, Huihui, Wang, Yongkun, Ouyang, Jian, Xie, Lu, Wu, Xiaojian, Wang, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987912/
https://www.ncbi.nlm.nih.gov/pubmed/35402221
http://dx.doi.org/10.3389/fonc.2022.848783
_version_ 1784682846988795904
author You, Weiqiang
Cai, Zerong
Sheng, Nengquan
Yan, Li
Wan, Huihui
Wang, Yongkun
Ouyang, Jian
Xie, Lu
Wu, Xiaojian
Wang, Zhigang
author_facet You, Weiqiang
Cai, Zerong
Sheng, Nengquan
Yan, Li
Wan, Huihui
Wang, Yongkun
Ouyang, Jian
Xie, Lu
Wu, Xiaojian
Wang, Zhigang
author_sort You, Weiqiang
collection PubMed
description BACKGROUND: Patients with stage I-III gastric cancer (GC) undergoing R0 radical resection display extremely different prognoses. How to discriminate high-risk patients with poor survival conveniently is a clinical conundrum to be solved urgently. METHODS: Patients with stage I-III GC from 2010 to 2016 were included in our study. The associations of clinicopathological features with disease-free survival (DFS) and overall survival (OS) were examined via Cox proportional hazard model. Nomograms were developed which systematically integrated prognosis-related features. Kaplan–Meier survival analysis was performed to compare DFS and OS among groups. The results were then externally validated by The Sixth Affiliated Hospital, Sun Yat-sen University. RESULTS: A total of 585 and 410 patients were included in the discovery cohort and the validation cohort, respectively. T stage, N stage, lymphatic/vascular/nerve infiltration, preoperative CEA, and CA19-9 were independent prognostic factors (P < 0.05). Two prognostic signatures with a concordance index (C-index) of 0.7502 for DFS and 0.7341 for OS were developed based on the nomograms. The 3-year and 5-year calibration curves showed a perfect correlation between predicted and observed outcomes. Patients were divided into three risk groups (low, intermediate, high), and distinct differences were noticed (p < 0.001). Similar results were achieved in the validation cohort. Notably, a free website was constructed based on our signatures to predict the recurrence risk and survival time of patients with stage I-III GC. CONCLUSIONS: The signatures demonstrate the powerful ability to conveniently identify distinct subpopulations, which may provide significant suggestions for individual follow-up and adjuvant therapy.
format Online
Article
Text
id pubmed-8987912
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89879122022-04-08 Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer You, Weiqiang Cai, Zerong Sheng, Nengquan Yan, Li Wan, Huihui Wang, Yongkun Ouyang, Jian Xie, Lu Wu, Xiaojian Wang, Zhigang Front Oncol Oncology BACKGROUND: Patients with stage I-III gastric cancer (GC) undergoing R0 radical resection display extremely different prognoses. How to discriminate high-risk patients with poor survival conveniently is a clinical conundrum to be solved urgently. METHODS: Patients with stage I-III GC from 2010 to 2016 were included in our study. The associations of clinicopathological features with disease-free survival (DFS) and overall survival (OS) were examined via Cox proportional hazard model. Nomograms were developed which systematically integrated prognosis-related features. Kaplan–Meier survival analysis was performed to compare DFS and OS among groups. The results were then externally validated by The Sixth Affiliated Hospital, Sun Yat-sen University. RESULTS: A total of 585 and 410 patients were included in the discovery cohort and the validation cohort, respectively. T stage, N stage, lymphatic/vascular/nerve infiltration, preoperative CEA, and CA19-9 were independent prognostic factors (P < 0.05). Two prognostic signatures with a concordance index (C-index) of 0.7502 for DFS and 0.7341 for OS were developed based on the nomograms. The 3-year and 5-year calibration curves showed a perfect correlation between predicted and observed outcomes. Patients were divided into three risk groups (low, intermediate, high), and distinct differences were noticed (p < 0.001). Similar results were achieved in the validation cohort. Notably, a free website was constructed based on our signatures to predict the recurrence risk and survival time of patients with stage I-III GC. CONCLUSIONS: The signatures demonstrate the powerful ability to conveniently identify distinct subpopulations, which may provide significant suggestions for individual follow-up and adjuvant therapy. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987912/ /pubmed/35402221 http://dx.doi.org/10.3389/fonc.2022.848783 Text en Copyright © 2022 You, Cai, Sheng, Yan, Wan, Wang, Ouyang, Xie, Wu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
You, Weiqiang
Cai, Zerong
Sheng, Nengquan
Yan, Li
Wan, Huihui
Wang, Yongkun
Ouyang, Jian
Xie, Lu
Wu, Xiaojian
Wang, Zhigang
Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title_full Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title_fullStr Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title_full_unstemmed Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title_short Construction and Validation of Convenient Clinicopathologic Signatures for Predicting the Prognosis of Stage I-III Gastric Cancer
title_sort construction and validation of convenient clinicopathologic signatures for predicting the prognosis of stage i-iii gastric cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987912/
https://www.ncbi.nlm.nih.gov/pubmed/35402221
http://dx.doi.org/10.3389/fonc.2022.848783
work_keys_str_mv AT youweiqiang constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT caizerong constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT shengnengquan constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT yanli constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT wanhuihui constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT wangyongkun constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT ouyangjian constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT xielu constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT wuxiaojian constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer
AT wangzhigang constructionandvalidationofconvenientclinicopathologicsignaturesforpredictingtheprognosisofstageiiiigastriccancer